Ranbaxy's Singh brothers known for lucky timing find time in short supply

Singh brothers face legal woes from 2008 sale of Ranbaxy

The Singh brothers are serial entrepreneurs known for pulling off one of the best-timed exits in the annals of Indian business. 

In 2008, they agreed to sell their family firm and India’s largest drugmaker, Ranbaxy Laboratories, to Japan’s Daiichi Sankyo Co for $4.6 billion — just months before the US Food and Drug Administration (FDA) banned imports at two of its Indian plants. That same year the US Department of Justice launched a probe, eventually resulting in a guilty plea by Ranbaxy and a $500-million fine for selling adulterated drugs. The Singhs were not named in the Ranbaxy probe.

Now,